Back to top
more

Teleflex (TFX)

(Delayed Data from NYSE)

$201.92 USD

201.92
640,750

-1.58 (-0.78%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $201.74 -0.18 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (89 out of 251)

Industry: Medical - Instruments

Zacks News

Teleflex (TFX) Hurt by Urolift Cancellations, Cost Woes

Teleflex (TFX) continues to face supply-chain challenges and freight logistic delays.

Teleflex (TFX) Q4 Earnings & Revenues Top Estimates, Margins Up

Strong segmental performance in the domestic and international markets is driving Teleflex's (TFX) fourth-quarter top line.

Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates

Teleflex (TFX) delivered earnings and revenue surprises of 1.98% and 1.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Steris (STE) Surpasses Q3 Earnings Estimates

Steris (STE) delivered earnings and revenue surprises of 8.72% and 0.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) Banks on Urolift Growth Amid Rising Expenses

Despite reporting softer-than-expected revenues for the third quarter, Teleflex (TFX) notes that customer preference for UroLift continues to be driven by strong clinical results.

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

Investors are optimistic about Teleflex (TFX) owing to better-than-anticipated results in the third quarter and strength in the Vascular business.

Teleflex (TFX) Q3 Earnings Top Estimates, Full-Year EPS View Up

Teleflex (TFX) reports better-than-expected earnings and revenues with strong geographical performance driving the top line in third-quarter 2021.

Teleflex (TFX) Q3 Earnings and Revenues Surpass Estimates

Teleflex (TFX) delivered earnings and revenue surprises of 15.84% and 0.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) Earnings Expected to Grow: Should You Buy?

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Teleflex (TFX) Real-World Data Outcome Supports UroLift System

Teleflex's (TFX) new real-world data outcomes together with product launches demonstrate the importance of UroLift System for most BPH patients.

Teleflex (TFX) Rides on UroLift Growth, Hurt by Pandemic Woes

Teleflex (TFX) has decided to increase its investment in 2021 and run a national campaign for the full year.

Teleflex (TFX) Q2 Earnings Surpass Estimates, Margins Up

Teleflex (TFX) reports better-than-expected revenues with strong segmental and geographical performance driving the top line in second-quarter 2021.

Teleflex (TFX) Q2 Earnings and Revenues Top Estimates

Teleflex (TFX) delivered earnings and revenue surprises of 17.13% and 4.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) Earnings Expected to Grow: Should You Buy?

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Teleflex (TFX) Moves 3.8% Higher: Will This Strength Last?

Teleflex (TFX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's Why You Should Add Teleflex (TFX) to Your Portfolio

Strong segmental performance in America and Asia is driving the top line for Teleflex (TFX).

Globus Medical (GMED) Marks New Milestone for ExcelsiusGPS

Globus Medical's (GMED) ExcelsiusGPS Robotic Navigation system reaches new surgical milestone for spinal procedures.

National Vision (EYE) Banks on Partnerships Amid COVID-19 Woes

National Vision (EYE) is confident about its financial flexibility and liquidity helping it to navigate this pandemic.

Fresenius Medical's (FMS) Xenios Gets NMPA Nod for ECMO System

Fresenius Medical (FMS) company receives expedited approval from NMPA permitting the Xenios AG's console and patient kits for ECMO therapy in China.

Hologic (HOLX) COVID Test With Saliva Sample Gets CE Mark

Per Hologic (HOLX), saliva collection is noninvasive and painless. The availability of this alternative specimen type should facilitate screening at schools, workplaces and other settings.

Orthofix's (OFIX) SpinalStim Demonstrates Improved Fusion Rates

Orthofix's (OFIX) SpinalStim bone growth device demonstrates impressive fusion rates for patients recovering from lumbar fusion surgery.

Omnicell (OMCL)-Chartwell Partner to Implement IVX Workflow

Omnicell (OMCL) and Chartwell partner to implement Omnicell's IVX Workflow for the management of chemotherapy drug product preparations.

Masimo (MASI) Reports Study Findings Backing the SedLine

Masimo (MASI) releases new study findings assessing two parameters provided by the SedLine that exhibit high predictability for mortality 180 days after cardiac arrest.

Orthofix (OFIX) Launches FORZA Ti PLIF Spacer System in the US

Orthofix (OFIX) launches FORZA Ti PLIF Spacer System to improve posterior lumbar interbody fusion procedures in the United States.